NRX Pharmaceuticals Warrant
NRXPW
NRXPW was delisted on the 22nd of May, 2026.
4 hedge funds and large institutions have $6.16K invested in NRX Pharmaceuticals Warrant in 2025 Q1 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.
0.14% less ownership
Funds ownership: 0.65% → 0.51% (-0.14%)
20% less funds holding
Funds holding: 5 → 4 (-1)
39% less capital invested
Capital invested by funds: $10.2K → $6.16K (-$4K)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$2.63K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$2.02K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$503 |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Truist Financial
Charlotte,
North Carolina
| $3.65K | – | – | – |
|
|
WAM
2
Wolverine Asset Management
Chicago,
Illinois
| $1.43K | +$2.63K | +15,088 | +291% |
|
|
VF
3
Virtu Financial
New York
| $1K | -$2.02K | -11,549 | -45% |
|
|
4
UBS Group
Zurich,
Switzerland
| $73 | -$503 | -2,879 | -74% |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| – | -$2 | -15 | Closed |
|
NRXPW Hedge Fund Activity: Q1 2025 in Review
4 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals Warrant (NRXPW) for Q1 2025, worth a combined $6.16K — down 39% from $10.2K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of NRXPW and 0 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 1 added.
The largest buyer was Wolverine Asset Management, adding an estimated $2.63K. The largest seller was Virtu Financial, cutting an estimated $2.02K.
- 4 institutional investors held NRX Pharmaceuticals Warrant (NRXPW) as of Q1 2025, down from 5 in Q4 2024.
- Funds reported $6.16K of NRX Pharmaceuticals Warrant stock for Q1 2025, down 39% quarter-over-quarter.
- 0 funds opened new NRX Pharmaceuticals Warrant positions in Q1 2025 and 1 closed out, a net change of -1 holder.
- The largest NRX Pharmaceuticals Warrant buyer in Q1 2025 was Wolverine Asset Management, an estimated $2.63K added.
- The largest NRX Pharmaceuticals Warrant seller in Q1 2025 was Virtu Financial, an estimated $2.02K sold.
Based on aggregated 13F filings for Q1 2025.